Richard Neubig, M.D., Ph.D.

Professor Emeritus and Director, Drug Discovery Program, Pharmacology & Toxicology. Dr. Neubig received his B.S. in chemistry from the University of Michigan and M.D. and Ph.D. from the Harvard-MIT Program in Health Sciences and Technology. He joined the department of Pharmacology at UM in 1983. He studies GPCR signaling with an emphasis on drug discovery. More recently he has worked on Rho/MRTF gene transcription mechanisms in cancer, scleroderma, and other fibrotic diseases and his lab also studies a rare genetic epilepsy and movement disorder complex - the GNAO1 encephalopathies. He has founded two start-up companies – Argessin LLC and FibrosIX LLC. He was president of the American Society for Pharmacology and Experimental Therapeutics (ASPET) and Chair of the AAAS Pharmaceutical Sciences section.